Skip to main content

Table 4 Failure rates at Day 28 after PCR adjustment in the studies in Boende and Kabalo

From: Varying efficacy of artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies

Outcome

N

Boende

Kabalo

SP

76

AQ

66

AS+SP

61

AS+AQ

58

SP

48

AS+SP

49

AS+AQ

52

ETF, n (%)

2 (2.6)

0

0

0

8 (16.7)

0

0

LCF, n (%)

16 (21.0)

10 (15.1)

13 (21.3)

8 (13.8)

3 (6.3)

0

0

LPF, n (%)

1 (19.7)

7 (10.6)

7 (11.5)

3 (5.2)

0

0

0

Overall failure rate1

% [95% CI]

35.9

[27.0–46.7]

18.3

[11.6–28.1]

24.6

[16.6–35.5]

15.1

[8.6–25.7]

19.6

[11.4–32.7]

0

[0–5.8]2

0

[0–6.2]2

  1. WHO 2001 outcome definitions used.
  2. ETF: early treatment failure; LFU: lost to follow-up; LCF: late clinical failure; LFP: late parasitological failure; ACPRA: adequate clinical and parasitological response
  3. 1 Estimated by Kaplan-Meier Survival Analysis, reinfections censored on day endpoint classified. Patients with missing or unresolved PCR results censored on last day seen with negative malaria smear result.
  4. 2 One sided CI for a proportion calculated (Wilson method)
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us